Market-leading TEVAR Device is First to Surpass 100,000 Devices Distributed Worldwide
W. L. Gore & Associates (Gore) today announced the GORE® TAG® Thoracic Device family has exceeded 100,000 devices distributed worldwide. Built on more than 18 years of success in both clinical studies and real-world commercial use, this GORE TAG Thoracic Device family is the first in the market to reach this significant milestone.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160608005448/en/
GORE® TAG® Thoracic Device (Photo: Business Wire)
The latest in a series of “firsts” for this thoracic stent-graft family, this milestone continues to underscore Gore’s commitment to advancing endovascular aortic repair therapies.
- First to receive CE mark in Europe – 1998
- First to obtain FDA approval – 2005
- First to obtain approval in Japan – 2008
- First FDA approval for isolated lesions including traumatic transections* – 2012
- First FDA approval for aneurysms, transections, and all Type B dissections – 2013
- First to reach 100,000 devices distributed – 2016
As the market-leading thoracic endovascular (TEVAR) treatment solution in the U.S. since 2011, the Conformable GORE TAG Device is indicated in most geographical regions for aneurysms, isolated lesions including traumatic transections, and Type B dissections. Designed to offer a thoracic endovascular treatment option, the GORE TAG Devices offer a less-invasive alternative to conventional therapy. The stent-graft family has demonstrated reduced operative mortality and morbidity, providing patients with a safe and effective alternative to open repair treatments.**
“Physicians desire a singular device with proven results and durability across all etiologies. Gore is always responsive to finding clinical and practical solutions for our practice,” said Mark A. Farber, MD, vascular surgeon (aortic specialist), Chapel Hill, North Carolina. “The magnitude of reaching such a large milestone exemplifies the adoption of the Conformable GORE TAG Device as the standard of care in TEVAR treatment.”
Dr. Farber will speak to this achievement at the 2016 Vascular Annual Meeting during his presentation, “Durable TEVAR: Results from 100,000 GORE TAG Thoracic Devices distributed worldwide,” on Friday, June 10, at 1:00 pm EDT. Click here for more details.
The GORE TAG Device family is the most studied thoracic stent-graft available. Since the first clinical implant in 1998, the GORE TAG Thoracic Device family has been studied in 10 U.S. Food & Drug Administration-consented clinical studies, one European clinical trial (ADSORB), and one worldwide registry (GREAT).
“Our thoracic stent-graft is the trusted solution for TEVAR procedures, with more than half of all physicians choosing the device for even the most complex cases,” said Ryan Takeuchi, aortic business unit leader at Gore. “This confidence has been built on our nearly two decades of working closely with physicians to evolve the device — pioneering thoracic endovascular aortic repair therapy and delivering conformability without compromise.”
The Conformable GORE TAG Device is part of the growing family of endovascular products that share a mission to effectively treat aortic disease, backed by Gore’s highly rated clinical support team and educational offerings. Earlier this year, Gore announced it has also achieved 250,000 patients treated*** with the GORE® EXCLUDER® AAA Endoprosthesis, a minimally invasive treatment option for patients with abdominal aortic aneurysms (AAA), with a legacy of repositionability, durability, and patency.
For more information on Gore’s Aortic products, please visit www.goremedical.com/aortic.
*Conformable GORE TAG Device was approved in the U.S. for aneurysms in 2011.
**Based on data provided in: W. L. Gore & Associates, Inc. GORE® TAG® Thoracic Endoprosthesis Annual Clinical Update. Flagstaff, AZ: W. L. Gore & Associates, Inc., 2015.
***Based on the number of GORE® EXCLUDER® AAA Endoprosthesis Trunk-Ipsilateral Legs distributed.
At Gore Medical, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com.
Products listed may not be available in all markets. GORE®, TAG®, EXCLUDER®, and designs are trademarks of W. L. Gore & Associates.
Chempetitive Group for W. L. Gore & Associates
Andrea Vuturo, +1 (312) 997-2436
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom